NextCure, Inc.
NXTC
$12.20
$0.241.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.77% | -24.59% | -21.47% | -14.62% | -10.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.66% | -28.41% | 65.47% | -26.27% | -21.12% |
| Operating Income | 21.66% | 28.41% | -65.47% | 26.27% | 21.12% |
| Income Before Tax | 18.68% | 25.27% | -74.03% | 35.84% | 19.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.68% | 25.27% | -74.03% | 35.84% | 19.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.68% | 25.27% | -74.03% | 35.84% | 19.80% |
| EBIT | 21.66% | 28.41% | -65.47% | 26.27% | 21.12% |
| EBITDA | 20.28% | 28.68% | -68.80% | 26.74% | 21.28% |
| EPS Basic | 52.33% | 34.90% | -70.83% | 36.08% | 20.10% |
| Normalized Basic EPS | 52.33% | 34.90% | -70.83% | 24.92% | 20.10% |
| EPS Diluted | 52.33% | 34.90% | -70.83% | 36.08% | 20.10% |
| Normalized Diluted EPS | 52.33% | 34.90% | -70.83% | 24.92% | 20.10% |
| Average Basic Shares Outstanding | 70.59% | 14.79% | 1.87% | 0.37% | 0.37% |
| Average Diluted Shares Outstanding | 70.59% | 14.79% | 1.87% | 0.37% | 0.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |